New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting

Off Science and Research

Dateline City:
KENILWORTH, N.J.

First-Time Data from POLO Trial Evaluating LYNPARZA ® (olaparib) in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press Program

KEYTRUDA ® (pembrolizumab) Five-Year Survival Data in Advanced Non-Small Cell Lung Cancer (NSCLC) from KEYNOTE-001 Trial in ASCO Press Program

Overall Survival Data for KEYTRUDA in Metastatic Renal Cell Carcinoma (RCC), Recurrent/Metastatic Head and Neck Cancer and Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that new research from the company’s broad oncology
clinical development program will be presented at the 55th
Annual Meeting of the American Society of Clinical Oncology (ASCO) in
Chicago from May 31-June 4.

Language:
English

Contact:

Media Contacts:
Pamela Eisele
(267) 305-3558

Kristen Drake
(908) 740-1679

Investor Contacts:
Teri Loxam
(908) 740-1986

Michael DeCarbo
(908) 740-1807

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting »

About The Author